Quarterly ResultApr 26, 2026, 05:31 AM
ADPT 2025 Revenue $277M, +54.7%; MRD Revenue +46%
AI Summary
Adaptive Biotechnologies Corp reported strong financial and operational results for 2025, with revenue increasing to $277.0 million, a 54.7% rise from 2024, primarily driven by its minimal residual disease (MRD) business which grew 46%. The company also significantly reduced net cash used in operations by 52% to $46.0 million. Additionally, Adaptive announced its 2026 Annual Meeting of Shareholders for June 5, 2026, where shareholders will vote on the election of two Class I directors, an advisory approval of executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm.
Key Highlights
- 2025 Revenue $277.0M, up 54.7% from $179.0M in 2024.
- 2025 Net cash used in operations $46.0M, a 52% reduction from $95.2M in 2024.
- Cash, cash equivalents, marketable securities $227.2M as of Dec 31, 2025.
- Total MRD revenue $212.3M in 2025, up 46% from 2024.
- clonoSEQ test volume 105,587 tests, up 39% year-over-year.
- Entered two non-exclusive agreements with Pfizer in Dec 2025.
- 2026 Annual Meeting on June 5 to elect directors, approve executive compensation, ratify auditor.